Literature DB >> 33767797

Not just eosinophilic fasciitis.

Razvan Chirila1, Elena Raluca Cristea2, Monica Roxana Purcarea3, Laura Carina Tribus4,5.   

Abstract

This case report describes a rare case of progressive muscle weakness in a patient treated for eosinophilic fasciitis (EF) for many years before being diagnosed with a second autoimmune disease: dermatomyositis. Our case is a report of a 65-year-old male diagnosed with eosinophilic fasciitis 7 years before being evaluated in our service at Mayo Clinic in Jacksonville, Florida, due to progressive muscle weakness despite the chronic treatment with methotrexate. Contrast-enhanced magnetic resonance imaging of the lower extremity showed enhancement throughout the thigh musculature, which led us to pursue biopsies of the fascia and muscle in order to confirm the diagnosis of EF associated with myopathy. This case illustrates the need to consider the possibility of myopathy in patients diagnosed with EF whenever muscle weakness is more prominent than expected. ©2020 JOURNAL of MEDICINE and LIFE.

Entities:  

Keywords:  CDC – Center for Disease Control and Prevention; DM – Dermatomyositis; EF – Eosinophilic fasciitis; EMS – Eosinophilia-myalgia syndrome; MRI – Magnetic Resonance Imaging; MTX – Methotrexate; dermatomyositis; eosinophilia-myalgia syndrome; eosinophilic fasciits; scleroderma

Mesh:

Substances:

Year:  2021        PMID: 33767797      PMCID: PMC7982268          DOI: 10.25122/jml-2021-0015

Source DB:  PubMed          Journal:  J Med Life        ISSN: 1844-122X


  10 in total

1.  Proceedings: Eosinophilic fasciitis. Report of six cases of a newly recognized scleroderma-like syndrome.

Authors:  G P Rodnan; A DiBartolomeo; T A Medsger
Journal:  Arthritis Rheum       Date:  1975 Sep-Oct

2.  Eosinophilic fasciitis: spectrum of MRI findings.

Authors:  Stacy J Moulton; Mark J Kransdorf; William W Ginsburg; Andy Abril; Scott Persellin
Journal:  AJR Am J Roentgenol       Date:  2005-03       Impact factor: 3.959

3.  Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Authors:  Jeffrey A Allen; Alicia Peterson; Robert Sufit; Monique E Hinchcliff; J Matthew Mahoney; Tammara A Wood; Frederick W Miller; Michael L Whitfield; John Varga
Journal:  Arthritis Rheum       Date:  2011-11

Review 4.  Eosinophilic fasciitis.

Authors:  J A Doyle; W W Ginsburg
Journal:  Med Clin North Am       Date:  1989-09       Impact factor: 5.456

5.  Eosinophilic fasciitis: clinical characteristics and response to methotrexate.

Authors:  Florentina Berianu; Marc D Cohen; Andy Abril; William W Ginsburg
Journal:  Int J Rheum Dis       Date:  2014-12-20       Impact factor: 2.454

6.  Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use.

Authors:  J Varga; R Griffin; J H Newman; S A Jimenez
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

7.  Rituximab in the treatment of dermatomyositis: an open-label pilot study.

Authors:  Todd D Levine
Journal:  Arthritis Rheum       Date:  2005-02

Review 8.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 9.  Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis, and related disorders.

Authors:  P H Plotz; M Dalakas; R L Leff; L A Love; F W Miller; M E Cronin
Journal:  Ann Intern Med       Date:  1989-07-15       Impact factor: 25.391

10.  Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort.

Authors:  Cecilie Dobloug; Torhild Garen; Helle Bitter; Johan Stjärne; Guri Stenseth; Lars Grøvle; Marthe Sem; Jan Tore Gran; Øyvind Molberg
Journal:  Ann Rheum Dis       Date:  2014-04-02       Impact factor: 19.103

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.